Cabot Corp (CBT)
NYSEMaterialsChemicals - SpecialtySnapshot 2026-11-04
$75.10+4.31%
Close 2026-11-04 · 1-day change
NYSEMaterialsChemicals - SpecialtySnapshot 2026-11-04
Research Workspace
Put CBT beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Materials: fringe margins under pressure (0q confirmed)
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — EPS near $6.25 in Q3 2026: Diluted EPS: $0.12 per share.
View ThesisRevenue is contracting — down about 5% over the past year.
View GrowthRanks among the strongest in its industry on quality — around the top 18%.
View QualityManagement screens strong on capital allocation, earnings delivery, margins, the balance sheet.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskCabot's earnings power has to keep compounding to justify the price. Revenue growth is steady, and the latest quarter beat estimates. The company delivered adjusted EPS of $6.42 for fiscal 2026. It trades at 12 times earnings versus a 16 times peer median. The price reflects less growth than we forecast. The primary pillar is under pressure with Q3 EPS at $0.12. Peer multiples imply a price about 15% above where it trades. The thesis is on watch, and this read is provisional.
Trailing returns as of 2026-11-04. CBT is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 6 analysts currently covering CBT (as of Nov 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare CBT with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| CBT Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 12 valuation methods, at three horizons. As of 2026-11-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Diversified Chemicals — fair value, gap to price, and forward P/E.
Compare the value case
Put CBT next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Deliver Adjusted EPS in range $6.00 to $6.50 for fiscal 2026
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-11-04. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Guidance confirms continued EPS growth trajectory.
Threatens: Leadership transition with new CEO Erica McLaughlin
CEO stock sale raises concerns about leadership stability.
Threatens: Leadership transition with new CEO Erica McLaughlin
CEO stock sale raises concerns about leadership stability.
Advances: Drive growth in Battery Materials segment
Battery Materials segment growth supports management's growth objective.
Downgrade suggests potential challenges to growth expectations.
Advances: Leadership transition with new CEO Erica McLaughlin
New CEO may enhance leadership and strategic direction.
CEO transition may disrupt operational stability.
Advances: Maintain strong cash flow from operations
Growing demand supports strong cash flow from operations.